<i>IN VITRO</i> STUDIES WITH HELA CELL LINES SENSITIVE AND RESISTANT TO ACTINOMYCIN D

Goldstein, Milton N.; Slotnick, Irving J.; Journey, L. J.

doi:10.1111/j.1749-6632.1960.tb20171.x

Cited by 79 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pro-megakaryocytic (HEL)4344, T-cell lymphoma (KT1)45, B-cell lymphoma (Raji)46, erythroleukemia (K562)47, and epithelial (HeLa)48 cells were obtained from American Type Culture Collection (Rockville, MD, USA).…”

Section: Methodsmentioning

confidence: 99%

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

et al. 2013

View full text Add to dashboard Cite

It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated blood platelets mediate the primary response to vascular injury, we hypothesize that storage of coagulation Factor VIII within platelets may provide a locally inducible treatment to maintain haemostasis for haemophilia A. Here we show that haematopoietic stem cell gene therapy can prevent the occurrence of severe bleeding episodes in dogs with haemophilia A for at least 2.5 years after transplantation. We employ a clinically relevant strategy based on a lentiviral vector encoding the ITGA2B gene promoter, which drives platelet-specific expression of human FVIII permitting storage and release of FVIII from activated platelets. One animal receives a hybrid molecule of FVIII fused to the von Willebrand Factor propeptide-D2 domain that traffics FVIII more effectively into α-granules. The absence of inhibitory antibodies to platelet-derived FVIII indicates that this approach may have benefit in patients who reject FVIII replacement therapies. Thus, platelet FVIII may provide effective long-term control of bleeding in patients with haemophilia A.

show abstract

Section: Methodsmentioning

confidence: 99%

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

et al. 2013

View full text Add to dashboard Cite

show abstract

“…of California Health Center, Sacramento, CA, USA. SW480 [37]; Caco-2 [38]; 293T [39] and HeLa [40]; and HuH-7 [41], ACHN [42], and SN12C [43] were obtained from Ken Kaplan; Bo Lonnerdal; Martin L. Privalsky; and Robert Weiss respectively, all from the Univ. of California, Davis, CA, USA.…”

Section: Cell Culturesmentioning

confidence: 99%

Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2

Tanaka

Kamita

Wolf

et al. 2008

Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanism

View full text Add to dashboard Cite

Soluble epoxide hydrolase (sEH) is a multifunctional protein encoded by the EPHX2 gene. The biological functions and enzyme kinetics of sEH have been extensively investigated, however, little is known about its transcriptional regulation and mechanisms of tissue specific expression. Here, a luciferase gene based reporter assay was used to identify the minimal promoter and cis regulatory elements of EPHX2. The minimal promoter was identified as a GC-rich region between nts −374 to +28 with respect to the putative transcriptional start site. A reporter plasmid carrying this minimal promoter showed higher or similar activities in comparison to a reporter plasmid carrying nts −5,974 to +28 of EPHX2 in 9 human cell lines that were tested. Sp1 binding sites that are involved in augmenting the minimal promoter activity of EPHX2 were identified by nested deletion analysis, site-specific mutation, electrophoretic mobility shift assay, and chromatin immunoprecipitation assay.

show abstract

“…Acquired MDR has been intensively studied and the basic science is well-established. Over 50 years ago, Goldstein and colleagues described a HeLa subline with actinomycin D resistance following intermittent exposure 6 . Some 10 years later, June Biedler selected Chinese hamster lung and fibroblast cells in actinomycin D and found the selected cells resistant to the selecting agent, as well as to vinblastine, vincristine, and daunomycin 7 .…”

Section: Introductionmentioning

confidence: 99%

Revisiting the role of ABC transporters in multidrug-resistant cancer

et al. 2018

View full text Add to dashboard Cite

Most patients who die of cancer have disseminated disease that has become resistant to multiple therapeutic modalities. Ample evidence suggests that the expression of ATP-binding cassette (ABC) transporters, especially the multidrug resistance protein 1 (MDR1, also known as P-glycoprotein or P-gp), which is encoded by ABC subfamily B member 1 (ABCB1), can confer resistance to cytotoxic and targeted chemotherapy. However, the development of MDR1 as a therapeutic target has been unsuccessful. At the time of its discovery, appropriate tools for the characterization and clinical development of MDR1 as a therapeutic target were lacking. Thirty years after the initial cloning and characterization of MDR1 and the implication of two additional ABC transporters, the multidrug resistance-associated protein 1 (MRP1; encoded by ABCC1)), and ABCG2, in multidrug resistance, interest in investigating these transporters as therapeutic targets has waned. However, with the emergence of new data and advanced techniques, we propose to re-evaluate whether these transporters play a clinical role in multidrug resistance. With this Opinion article, we present recent evidence indicating that it is time to revisit the investigation into the role of ABC transporters in efficient drug delivery in various cancer types and at the blood-brain barrier.

show abstract

IN VITRO STUDIES WITH HELA CELL LINES SENSITIVE AND RESISTANT TO ACTINOMYCIN D

Cited by 79 publications

References 8 publications

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A

Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2

Revisiting the role of ABC transporters in multidrug-resistant cancer

Contact Info

Product

Resources

About